Krsnaa Diagnostics Gains Approval for Promoter Warrant Issue

Issue price set at Rs 566 per warrant for 16,21,000 units.
BSE documentation rectification pending following initial in-principle approval from exchanges.

Reader Takeaway: Promoter-led capital infusion proceeds as regulatory clearances arrive, pending minor administrative fix from the BSE.

What just happened

Krsnaa Diagnostics Limited has secured the mandatory in-principle approval from both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) for its proposed preferential issue of 16,21,000 convertible warrants. These warrants, carrying a face value of Rs 5 each, are being allotted to the Promoter and Promoter Group at a fixed price of Rs 566 per warrant.

Why this matters

The preferential allotment is a strategic move to raise capital from insiders, signaling promoter confidence in the company’s growth trajectory. For retail investors, the approval is a critical step in the company's capital raising exercise, which will eventually see these warrants converted into equity shares, impacting the overall share capital structure.

The backstory

The company announced its intention to move forward with this preferential issue to strengthen its balance sheet. While the process has moved to the approval stage, the company noted that the current approval letter from the BSE includes minor factual inaccuracies. Krsnaa Diagnostics is actively coordinating with the exchange to obtain a rectified version of the document to ensure all administrative filings are accurate.

What to track next

Investors should look for the company's follow-up update regarding the receipt of the corrected BSE approval letter. Once finalized, this will pave the way for the actual allotment and subsequent warrant conversion process, which is the next key milestone for shareholders to track.